Winslow Evans & Crocker’s Heron Therapeutics HRTX Stock Holding History

Winslow Evans & Crocker’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	$0	Hold	1	–	–	﹤0.01%	1335
2020 Q3	$0	Hold	1	–	–	﹤0.01%	1121
2020 Q2	$0	Sell	1 -1	-50%	-$16	﹤0.01%	1146
2020 Q1	$2K	Hold	2	–	–	﹤0.01%	1017
2019 Q4	$2K	Hold	2	–	–	﹤0.01%	1086
2019 Q3	$2K	Hold	2	–	–	﹤0.01%	1078
2019 Q2	$2K	Hold	2	–	–	﹤0.01%	1076
2019 Q1	$2K	Hold	2	–	–	﹤0.01%	1172
2018 Q4	$2K	Hold	2	–	–	﹤0.01%	1020
2018 Q3	$2K	Hold	2	–	–	﹤0.01%	1034
2018 Q2	$2K	Hold	2	–	–	﹤0.01%	1043
2018 Q1	$28	Hold	2	–	–	﹤0.01%	1124
2017 Q4	$20	Hold	2	–	–	﹤0.01%	1123
2017 Q3	$18	Buy	2 +1	+100%	+$16	﹤0.01%	1113
2017 Q2	$14	Sell	1 -1	-50%	-$14	﹤0.01%	1270
2017 Q1	$16	Hold	2	–	–	﹤0.01%	1238
2016 Q4	$14	Hold	2	–	–	﹤0.01%	1246
2016 Q3	$18	Hold	2	–	–	﹤0.01%	1289
2016 Q2	$20	Buy	2 +1	+100%	+$20	﹤0.01%	1280
2016 Q1	$19	Sell	1 -1	-50%	-$20	﹤0.01%	1282
2015 Q4	$28	Hold	2	–	–	﹤0.01%	1362
2015 Q3	$26	Hold	2	–	–	﹤0.01%	1290
2015 Q2	$32	Hold	2	–	–	﹤0.01%	1298
2015 Q1	$16	Hold	2	–	–	﹤0.01%	1271
2014 Q4	$12	Hold	2	–	–	﹤0.01%	1293
2014 Q3	$10	Buy	2 +1	+100%	+$9	﹤0.01%	1381
2014 Q2	$12	Hold	1	–	–	﹤0.01%	1295
2014 Q1	$14	Buy	+1	New	+$13	﹤0.01%	1280

Other funds holding HRTX

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Winslow Evans & Crocker's HRTX Position: Q4 2020 in Review

Winslow Evans & Crocker held its Heron Therapeutics (HRTX) position steady in Q4 2020 at 1 share worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #1335.

Winslow Evans & Crocker first reported a position in HRTX in Q1 2014 and has held it in 28 quarters since. The position peaked at $2K in Q1 2020. 189 funds tracked by Wall St. Rank hold HRTX as of Q4 2020.

Winslow Evans & Crocker held 1 share of Heron Therapeutics worth $0 as of Q4 2020.
Winslow Evans & Crocker left its Heron Therapeutics share count unchanged in Q4 2020.
Heron Therapeutics made up ﹤0.01% of Winslow Evans & Crocker's portfolio in Q4 2020, its #1335 holding.
Winslow Evans & Crocker first reported a position in Heron Therapeutics in Q1 2014 and has held it in 28 quarters since.
Winslow Evans & Crocker's Heron Therapeutics position peaked at $2K in Q1 2020.
189 funds tracked by Wall St. Rank held Heron Therapeutics as of Q4 2020.

Based on Winslow Evans & Crocker's 13F filing for Q4 2020, filed 3 Feb 2021.